GLJ Research is zeroing out its Tilray Inc TLRY price target in the wake of the cannabis company's fourth-quarter report Monday
The Tilray Analyst
Gordon Johnson II maintained a Sell rating and lowered the price target for Tilray from $5 to $0, suggesting the equity is essentially worthless.
The Tilray Thesis
The 8.2% quarter-over-quarter drop in Tilray's fourth-quarter revenue should set off an alarm bell, given the shares are trading at a 3.3 times forward price-to-sales multiple, Johnson said in a Wednesday note. (See his track record here.)
Tilray took $68.6 million in inventory valuation adjustments in the fourth quarter, which equates to more than 41% of the company's full-year sales, the analyst said.
"In fact, even after adjusting 70% of its 4Q19 losses away, TLRY's 4Q19 non-GAAP loss was over 36% more than its 4Q19 revenue."
Despite the $70 million at-the-market stock issuance in the fourth quarter and an incremental debt offering of $2.23 million, Tilray's fourth-quarter cash and investments balance fell $26 million from the previous quarter, suggesting a quarterly cash burn rate of $98 million, Johnson said.
A collateral-based funding arrangement is unlikely, given more than 43% of balance sheet assets are made up of goodwill and intangible assets, he said.
"Thus, while TLRY is guiding to positive EBITDA by 4Q20, with its performance sharply lagging bottom line 2019 GAAP EPS expectations thru 2019, we see this forecast as aspirational."
Tilray issued $60 million debt in late February bearing an interest rate of about 12%, entailing quarterly interest expenses of $7 million, Johnson said.
This suggests the credit markets see elevated risk in the company's near-to-intermediate term outlook, according to GLJ Research.
TLRY Price Action
Tilray shares were slipping 10.87% to $11.15 at the time of publication Thursday.
Related Links:
Tilray, Aurora Cannabis Layoffs May Signal Industrywide Problem
Cannabis Countdown: Top 10 Marijuana Stock News Stories Of The Week
Lee también: Acciones de Tilray (TLRY) y Aurora Cannabis (ACB) Continuan Al Alza: ¿Por Qué?
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.